Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from iTeos Therapeutics ( (ITOS) ) is now available.
On May 13, 2025, iTeos Therapeutics and GlaxoSmithKline (GSK) announced the termination of their collaboration and license agreement, originally established in June 2021, following interim results from the GALAXIES Lung-201 study. The study, which assessed the combination of belrestotug and dostarlimab in non-small cell lung cancer, did not meet the criteria for progression-free survival improvements, leading to the decision to end the belrestotug development program. This termination will result in the cessation of financial obligations between the two companies and the end of new enrollment in ongoing trials. iTeos plans to explore strategic alternatives to maximize shareholder value, despite the disappointing trial results.
The most recent analyst rating on (ITOS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.
Spark’s Take on ITOS Stock
According to Spark, TipRanks’ AI Analyst, ITOS is a Neutral.
iTeos Therapeutics’ overall stock score is primarily impacted by its financial difficulties, including declining profitability and cash flow issues. The technical analysis suggests some potential for upward momentum, but the stock’s valuation is a significant drawback due to its negative P/E ratio. Investors should be cautious and consider the company’s ability to improve its financial performance before investing.
To see Spark’s full report on ITOS stock, click here.
More about iTeos Therapeutics
iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immuno-oncology therapeutics. The company leverages its expertise in tumor immunology and immunosuppressive pathways to create novel product candidates aimed at restoring immune responses against cancer. iTeos is headquartered in Watertown, MA, with a research center in Gosselies, Belgium.
Average Trading Volume: 431,636
Technical Sentiment Signal: Sell
Current Market Cap: $264.9M
See more insights into ITOS stock on TipRanks’ Stock Analysis page.